Abstract-As a leading cause of death worldwide, cardiovascular disease is a global health concern. The development and progression of atherosclerosis, which ultimately gives rise to cardiovascular disease, has been causally linked to hypercholesterolemia. Mechanistically, the interplay between lipids and the immune system during plaque progression significantly contributes to the chronic inflammation seen in the arterial wall during atherosclerosis. Localized inflammation and increased cell-to-cell interactions may influence polarization and proliferation of immune cells via changes in amino acid metabolism. Specifically, the amino acids l-arginine (Arg), l-homoarginine (hArg) and l-tryptophan (Trp) have been widely studied in the context of cardiovascular disease, and their metabolism has been established as key regulators of vascular homeostasis, as well as immune cell function. Cyclic effects between endothelial cells, innate, and adaptive immune cells exist during Arg and hArg, as well as Trp metabolism, that may have distinct effects on the development of atherosclerosis. In this review, we describe the current knowledge surrounding the metabolism, biological function, and clinical perspective of Arg, hArg, and Trp in the context of atherosclerosis.
ardiovascular disease (CVD) constitutes the leading cause of death worldwide accounting for ≈1 of every 3 deaths in the United States 1 and 45% of all deaths in Europe 2 with atherosclerosis being the major underlying pathology. The development and progression of atherosclerosis have been causally linked to increased blood lipid levels, namely hypercholesterolemia. 3 Additional risk factors including smoking, age, lack of physical exercise, and comorbidities also correlate with an increased incidence of CVD; however, previous research has firmly established atherosclerosis as a lipoproteindriven disease. [4] [5] [6] Although atherosclerosis has been accepted as a chronic inflammatory condition, current therapies tend to focus on lipid-lowering rather than the inflammatory response. Food and Drug Administration-approved therapies, such as statins and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, actively focus on reducing LDL (low-density lipoprotein) cholesterol, whereas experimental therapies involving HDL (high-density lipoprotein) cholesterol aim to rebalance malfunctioning cholesterol efflux mechanisms. [7] [8] [9] Unfortunately, therapies targeting lipid levels may not be adequate for all patients as these therapies are associated with suboptimal adherence rates, as well as intolerance in special cases. 10, 11 Therefore, there is still a need for additional therapeutics which may address personalized requirements. With this in mind, the pivotal CANTOS (Canakinumab Antiinflammatory Thrombosis Outcomes Study), which validated the inflammatory hypothesis of atherosclerosis, spurred continued research into the interplay between lipids and the immune system during atherosclerotic plaque progression. 12 Specifically, immune barriers, such as endothelial cells (ECs), as well as innate and adaptive immune cell populations, have displayed distinct dysfunctions under atherosclerotic conditions, which may be related to certain amino acids (AAs) and their metabolism. The AAs l-arginine (Arg), l-homoarginine (hArg), and l-tryptophan (Trp) have been widely discussed in the context of CVD, and their roles in vascular homeostasis and immune regulation are generally accepted. Here, we summarize the current knowledge on Arg, hArg, and Trp metabolism, their biological function, and their relevance as putative therapeutic targets in atherosclerosis.
Please see https://www.ahajournals.org/atvb/ atvb-focus for all articles published in this series.
AAs and Their Metabolism
To date, ≈500 naturally occurring AAs are known, and among them, only 20 standard AAs appear in the genetic code. Typically, AAs serve as basic components for protein synthesis usually as metabolites or intermediates in cellular pathways where they constitute an important energy source in addition to glucose and fatty acids. Although all AAs are important for metabolism and protein synthesis, 3 particular AAs have recently generated interest in the field of CVD. In this review, we will focus specifically on Arg, hArg, and Trp to summarize the current knowledge on their metabolism, biological function and clinical perspective in the context of atherosclerosis.
Arginine
Decades of research have clearly demonstrated the importance of Arg in the physiology and pathophysiology of both steady state and disease state conditions, including CVD. Considering Arg is the precursor for NO, a key metabolite for vascular function and tone, Arg and its metabolism has piqued significant interest in cardiovascular research. Although much research has focused on endothelium-dependent Arg effects, 13, 14 endothelium-independent effects were recently described to regulate immune cell responses as well, which will be described in-depth in later sections. Physiologically, the body is able to meet its requirements for Arg either exogenously through diet and subsequent proteolysis or endogenously through de novo synthesis within the urea cycle. Although the metabolism of Arg represents a fairly complex set of reactions, 3 key pathways help form its role within atherosclerosis ( Figure 1A) . First, during de novo synthesis, Arg is produced from citrulline within the urea cycle. Although Arg synthesis is mostly restricted to liver, cells unable to synthesize Arg can import extracellular Arg via CAT (cationic amino acid transporters) of the SLC7 (high-affinity cationic amino acid transporter encoded by the SLC7A gene) family to metabolize Arg for their demands and cellular functions. 15, 16 After uptake, Arg is metabolized either by ARG (arginase) or NOS (NO synthase). Importantly, ARG exists in 2 different isoforms with distinct expression patterns: ARG1 that is mainly expressed in the liver where it functions as part of the urea cycle or mitochondrial ARG2 that is expressed in the kidney where its function remains unresolved. Ultimately, though, both enzymes catalyze the formation of urea and ornithine from Arg. Similarly, the second family of Arg-metabolizing enzymes, NOS, also exists in various isoforms: nNOS (neuronal NOS), macrophage-expressed iNOS (inducible NOS), and eNOS (endothelial NOS). All NOS isoforms require calmodulin and tetrahydrobiopterin to catalyze the conversion of Arg to NO and citrulline. In the endothelium, NO diffuses over a short distance to vascular smooth muscle cells (VSMCs) where it is used by sGC (soluble guanylate cyclase) to form cGMP, which permits VSMC relaxation. 17 During inflammation, ARG1 and iNOS expression is orchestrated by a variety of cytokines. iNOS is induced by proinflammatory cytokines, such as IL (interleukin)-1, TNF-α (tumor necrosis factor α), IFN-γ (interferon γ), or lipopolysaccharides. However, ARG1 expression is induced by anti-inflammatory cytokines, such as IL-4, IL-6, IL-10, IL-13, or TGF (transforming growth factor)-β, [18] [19] [20] [21] which coincides with an increase in SLC7A expression to import Arg. 22, 23 Finally, Arg serves as a substrate for AGAT (l-arginine:glycine amidinotransferase), the first and ratelimiting enzyme in the creatine biosynthesis that catalyzes the formation of the intermediate guanidino acetic acid from Arg and glycine. 24, 25 Thus, Arg constitutes a pivotal precursor in creatine and energy metabolism.
Homoarginine
In recent years, a wealth of knowledge has been accumulating for hArg's role in CVD. 26 Structurally, hArg is closely related to Arg, but it differs in its role in protein synthesis considering hArg may be a nonproteinogenic AA. Nevertheless, hArg is still suggested as a substrate for NOS in various cell types positioning it as an additional therapeutic target in atherosclerosis. [27] [28] [29] To understand potential target mechanisms, we first must look at hArg's metabolism ( Figure 1B) .
In contrast to Arg, the majority of bioavailable hArg is most likely newly synthesized via 2 discrete pathways. First, genome-wide association studies identified the enzyme AGAT as the key enzyme for hArg biosynthesis. Both AGAT knockout mice and AGAT-deficient patients were used to prove that AGAT catalyzes the formation of hArg from 27, 36 Although physiological hArg concentrations have been established, 37 a recent study showed a recovery rate of 95% in urine after oral administration indicating limited catabolism of hArg in the body. 38 Nevertheless, hArg supplementation has been demonstrated to increase circulating hArg levels. 39 Similar to Arg, circulating hArg is also imported via AA transporters 40 where its intracellular functions are still incompletely understood.
Tryptophan
Considering its role in diverse biological processes, including neurological and immune functions, Trp remains a well-researched AA throughout recent years. Unlike Arg and hArg, Trp is an essential AA that cannot be synthesized endogenously and must be acquired through diet. Although its role in protein synthesis continues to be integral, its metabolism and downstream metabolites have also demonstrated clear effects within the body; thus, Trp represents an intriguing player during plaque progression. Understanding Trp metabolism is essential to piece together its effects on atherosclerosis ( Figure 1C) .
Within the body, Trp primarily initiates either the serotonin pathway or the kynurenine pathway. First, Trp can act as a substrate for serotonin and melatonin synthesis. Serotonin performs multiple functions, such as neurotransmission, in the central nervous system where its physiological levels are associated with anxiety and depression. In the periphery, it is also involved in thrombocyte aggregation, as well as blood pressure regulation. [41] [42] [43] [44] However, approximately only 10% of Trp enters the serotonin pathway, whereas the other 90% enters the kynurenine pathway. Here, Trp serves as a substrate for the is converted by OTC (ornithine transcarbamylase) to citrulline, which is further metabolized by ASS (argininosuccinate synthetase) and ASL (argininosuccinate lyase). NOS (nitric oxide synthase) and ARG (arginase) use Arg as a substrate to catalyze the formation of NO and urea, respectively. AGAT (l-arginine:glycine amidinotransferase) catalyzes the conversion from Arg and glycine to guanidino acetic acid, an intermediate which is further converted by GAMT (guanidoacetate methyltransferase) to form creatine. B, Metabolic pathways of dietary and de novo synthesized hArg. Endogenous hArg is generated by AGAT conversion from Arg and lysine (Lys). Alternatively, hArg may be synthesized via urea cycle enzymes (OTC, ASS, and ASL) from homocitrulline. Although hArg is predominantly excreted by the kidneys, intracellular hArg may serve as an alternative substrate for NOS, as well as putative inhibitor for ARG. C, Metabolic pathways of dietary Trp. Trp is metabolized by 2 distinct pathways: (1) Trp serves as a substrate for TPH (tryptophan hydroxylase) which generates 5-hydroxytryptophan and subsequently serotonin through AADC (amino acid decarboxylase) or (2) IDO (indoleamine 2,3-dioxygenase) and TDO (tryptophan 2,3-dioxygenase) catalyze the conversion of Trp to N-formyl-kynurenine that is further processed by KFase (N-formyl-kynurenine formamidase) into KYN (kynurenine). KYN is subsequently converted into KYN acid or into 3-hydroxykynurenine by KMO (kynurenine hydroxylase monooxygenase) which is further metabolized to 3-hydroxyanthranilic acid by KYNU (Kynureninase) and subsequently into quinolinic acid. Eventually, NAD+ is generated.
enzyme IDO (indoleamine 2,3-dioxygenase) to first be metabolized to N-formyl-kynurenine, which is further degraded into kynurenine. Kynurenic acid or 3-hydroxy-kynurenine are subsequently generated, the latter being further metabolized into 3-hydroxyanthranilic acid (3-HAA), quinolinic acid, and ultimately to pyridine nucleotide nicotinamide adenine dinucleotide (NAD + ), an electron/proton carrier (NADH) used in energy-producing pathways, such as glycolysis and citric acid cycle. Similar to the ARG enzyme, 2 isoforms of IDO exist. IDO1, typically expressed in lymphoid organs, is induced on inflammatory stimuli, including T helper (Th) 1 cytokines like IFN-γ. [45] [46] [47] IDO2, however, is an IDO1 paralog, which was only recently discovered and has not been well-studied yet. Interestingly, a third enzyme called TDO (tryptophan 1,2-dioxygenase) catalyzes the same reaction as IDO but is resistant to inflammatory stimuli and rather controls Trp homeostasis in the body. Together, IDO and TDO form the ratelimiting reaction within the kynurenine pathway. [48] [49] [50] [51] Atheroinflammation is crucially driven by various cytokines, including IL-6 and IFN-γ, which act as mediators and inducers of AA metabolism. Specifically, expression of iNOS and IDO can be controlled to shape the inflammatory response. Therefore, Arg, hArg, and Trp metabolism may crucially contribute to immune cell regulation in atherosclerosis, which will be further addressed below.
Immune Cells, Function, and Metabolism in Atherosclerosis
As previously mentioned, atherosclerosis is defined as a chronic inflammatory disease of the arterial wall. Various cell types are responsible for the persistent inflammation seen during plaque progression including ECs, innate immune cells, and adaptive immune cells. As a consequence of the proinflammatory environment seen within the plaque, cell-to-cell interactions increase substantially, which leads to changes in cell metabolism. In the following section, we will address the contribution of ECs, innate immune cells, and adaptive immune cells to plaque progression with a focus on the cellspecific effects of Arg, hArg, and Trp metabolism.
Endothelial Cells
Although not an immune cell per se, ECs and their AA metabolism play a decisive role in vascular homeostasis and pathogenesis of atherosclerosis. Physiologically, ECs express eNOS, which hydrolyzes Arg and potentially hArg into NO, which subsequently activates the NO/cGMP cascade in VSMCs leading to vasodilation (Figure 2A ). However, several atherosclerotic risk factors, such as low shear stress, oxidative stress or LDL, and modified LDL cholesterol, promote EC dysfunction. 52 In particular, limited bioavailability and activity of antithrombotic and antihypertensive molecules, such as Arg, eNOS, and NO may lead to eNOS uncoupling, a patho-physiological condition where eNOS produces superoxide instead of NO. 53, 54 Kuhlencordt et al 55 corroborated this idea using apoEknockout mice with eNOS deficiency, which displayed high blood pressure and aggravated atherosclerosis. With this in mind, NO, a key metabolite of Arg and hArg metabolism, plays a crucial role in vascular homeostasis solidifying it as atheroprotective functions.
More recently, a study identified a novel atheroprotective mechanism in EC Trp metabolism as well. Similar to Arg and hArg metabolism, the Trp metabolite kynurenine was found to significantly contribute to vasodilation during systemic inflammation (Figure 2A) . Interestingly, pharmacological inhibition of IDO increased blood pressure, whereas kynurenine decreased blood pressure in a dose-dependent manner in a hypertensive rat model. 56 Taken together, this indicated that both eNOS-and IDO-mediated metabolisms are crucial for control of blood vessel tone, and potential disruptions of these pathways under chronic inflammatory conditions, such as atherosclerosis, may contribute to plaque progression. Finally, atherogenic stimuli, such as LDL and modified LDL, strongly upregulated EC expression of cellular adhesion molecules, including selectins and vascular cell adhesion molecule. Various chemokines then recruit leukocytes, including both innate and adaptive immune cells, which attach to ECs and ultimately transmigrate into the vessel wall.
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Innate Immune Cells
The contribution of innate immune cells, including neutrophils and monocytes, to atherosclerosis has been well documented over several decades [60] [61] [62] [63] [64] [65] ; however, research into their AA metabolism is still limited in the context of CVD. Within the plaque, infiltrated monocytes transform into macrophages, which engulf oxLDL (oxidized LDL), as well as apoptotic cells. These macrophages may be polarized into subtypes, which metabolize Arg, hArg, and Trp in distinct pathways. Excessive phagocytosis of lipids in combination with a decrease in cholesterol efflux leads to the phenotypic change of macrophages into foam cells.
Typically, both neutrophils and monocytes exploit the glycolytic pathway for energy supply; however, screening of gene expression databases, including gexc.riken.jp and immgen.org, revealed neutrophils highly express ARG2 potentially for Arg metabolism but relatively low SLC7A (CAT) transporters to import extracellular Arg. Interestingly, in vivo studies using myeloid-derived suppressor cells, characterized as CD11b+ and Gr1+ cells, were able to demonstrate the induction of ARG1 and SLC7A1 transporter expression. 66 Thus, neutrophils potentially can deprive their environment of Arg, which in turn may affect surrounding cells in the local environment. 67, 68 Similarly, macrophages are also able to import environmental AAs to affect the function of surrounding cell subsets. Macrophages express all major enzymes for Arg, hArg, and Trp metabolism, including ARG1, iNOS, and IDO1, which allows them to have various immune regulatory capacities. A dichotomy is formed from polarized M1 and M2 macrophages that can be based on their metabolism. For example, M1 macrophages are classified based on their expression of iNOS, whereas M2 macrophages specifically express ARG1. 69 Interestingly, this expression pattern is cytokine-induced meaning surrounding cell subsets may substantially influence the polarization of plaque-laden macrophages. In particular, numerous studies have reported Th-cytokines can induce both iNOS and ARG1 expression in macrophages. Accordingly, Th1 cell-cytokines, such as TNF-α or IFN-γ, induce the expression of iNOS, whereas Th2 cell-cytokines, such as IL-4 or IL-13, induce ARG1 expression ( Figure 2B) . 18, 19, 21, 70, 71 The Trp metabolites 3-hydroxy-kynurenine, 3-HAA, and quinolinic acid have also been shown to modulate oxidative stress and damage reactions, such as lipid peroxidation, thus potentially acting anti as well as prooxidative. 72, 73 Specifically, 3-HAA was described to inhibit LDL lipid peroxidation, 74, 75 as well as iNOS expression, in macrophages. 76 To confound this, similar to neutrophils macrophages are also able to starve their local environment of specific AAs to ultimately regulate surrounding cells' function and proliferation. Hence, the local inflammatory environment in combination with AA bioavailability directs a complex set of interactions between innate and adaptive immune cells which may affect polarization and proliferation of both cell types.
Adaptive Immune Cells
Although several adaptive immune cell subsets have been established in the pathogenesis of atherosclerosis, T cells are of particular interest because of their specific interactions with innate immune cells with respect to their AA metabolism. Similar to lesional macrophages, adaptive immune cells, such as CD4+ T cells, may be activated and polarized towards distinct subsets depending on the local inflammatory environment. These T-cell subsets infiltrate the atherosclerotic lesion and change the local inflammatory environment causing cyclic effects between themselves and innate immune cells.
On activation, naive T cells shift towards the glycolytic pathway to ensure fast energy supply. 77, 78 Accordingly, AAs are then required to assure proper immune response for expansion and cytokine production, which allows for induction of AA transporter expression, such as SLC7A, in activated T cells as well. Mechanistically, Arg uptake and subsequent degradation by myeloid cells leads to starvation of T cells, which is sensed by T-cell stress kinase GCN2 (general control nonderepressible 2), a general sensor of AAs in the local environment. Arg depletion leads to GCN2 kinase activation that phosphorylates the eIF2α (eukaryotic initiation factor 2α), which in turn stalls protein translation. 81 Consequently, T cells stop proliferating and go into cell cycle arrest. 82 Furthermore, CD3ζ chain expression of the TCR (T-cell receptor) complex depends on Arg availability. The CD3ζ chain is 1 of 6 components that constitute the TCR and is crucial for T-cell development and differentiation ( Figure 2C) . 83, 84 Coculture experiments of macrophages together with isolated T cells corroborated that induction of both ARG1 and SLC7A1 in macrophages leads to rapid Arg depletion in media and a specific decrease in CD3ζ chain expression in T cells. 85 In addition to the myeloid-derived Arg starvation, myeloidderived NO has been shown to affect T-cell proliferation. iNOS-derived NO from macrophages and myeloid-derived suppressor cells was found to diminish T-cell proliferation by interfering with the traditional NO/cGMP signaling pathway and via inhibiting Jak3/STAT5 (Janus kinase signal transducer and activator of transcription) phosphorylation. 86, 87 Of note, IL-2/IL-2r (IL-2 receptor), which uses JAK/STAT, has been established as a pivotal pathway for T-cell differentiation and proliferation. Typically, regulatory T cells act as suppressors against the chronic inflammation seen during plaque progression. Interestingly, the IL-2r JAK3/ STAT5 axis is critical for development of regulatory T cells as the lineage-defining transcription factor forkhead box P3 (FoxP3) gene is activated ( Figure 2C ). 88 In contrast to these well-studied T-cell responses to myeloid-driven iNOS metabolism, knowledge on endogenous iNOS metabolism in T cells is still little. Endogenous iNOS expression has been confirmed in mouse and human Th17 cells and, although still vague, functional studies suggest that it regulates apoptosis and Th17 differentiation. 89, 90 Similarly, Trp metabolism crucially contributes to T-cell function as well as proliferation. Here, Trp metabolism also works either through metabolite deprivation or IDO-generated Trp metabolites, such as kynurenine, kynurenic acid, or 3-HAA. First, IFN-γ induces IDO activity in macrophages and dendritic cells, which subsequently leads to enhanced Trp metabolism and local Trp starvation. This phenomenon, similar to Arg starvation, has been shown to be sensed by the stress kinase GCN2-eIF2α axis, which ultimately leads to the arrest of T-cell proliferation and again downregulation of CD3ζ chain on CD8+ T cells. Later, myeloid-derived kynurenine further exerts immune suppressive functions by promoting regulatory T cell differentiation. [91] [92] [93] Similar anti-inflammatory effects have also been implicated for 3-HAA. 94 Mechanistically, activated T cells may induce IDO1 expression in dendritic cells through CTLA-4 (cytotoxic T lymphocyte-associated protein 4) thereby promoting their own immunosuppression. 95 Conversely, blocking of IDO in dendritic cells promotes T-cell differentiation towards Th17-like cells, rather than regulatory T cells, through dendritic cell secretion of IL-6.
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Cell polarization and phenotypic switching are key inflammatory mechanism of atherosclerosis; therefore, targeting metabolism, including Arg, hArg, and Trp, as well as their downstream metabolites, may provide interesting strategies for clinical interventions.
Clinical Perspective Arginine
Clinical and Epidemiological Evidence
The importance of Arg emerged in the late 1980s based on the recognition that Arg serves as a substrate for NO by the enzyme eNOS. 98 Since then a large amount of experimental and clinical research elaborated the role of the Arg/NO metabolism in atherosclerotic disease. 99 Therapeutically, the fundamental idea was to supplement Arg as a substrate for NOS in patients with impaired NO to improve endothelial function and thereby cardiovascular outcome. Although short-term clinical trials initially suggested a benefit, 100,101 long-term clinical studies supplementing Arg failed to improve cardiovascular outcome. In various cardiovascular entities, for example, coronary artery disease or peripheral arterial disease, oral Arg therapy did not improve vascular function when added to standard therapy. 102, 103 Similar results were obtained in patients with acute coronary syndrome when Arg was added to standard therapies, and beyond futility, concerning endothelial function, Arg was even associated with higher postinfarction mortality (http://www. clinicaltrials.gov. Unique identifier: NCT00051376). 104 In line, a recent Mendelian randomization study proposed that high Arg levels were associated with higher risk of ischemic heart disease. 105 Mechanisms implicated in the failure of Arg include insufficient amounts of the critical eNOS-cofactor tetrahydrobiopterin led to eNOS uncoupling or a boost of substrate and cofactor consumption by iNOS, which is highly expressed under atherosclerotic conditions.
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Experimental Evidence
To date, most of the Arg research in the cardiovascular field has focused on Arg's role as a regulator of vascular function. However, as discussed, ARG-and NOS-mediated Arg metabolism in immune cells crucially contributes to restrain inflammatory processes during atherogenesis. Thus, current research follows both mechanistic leads to ensure thorough elaboration of the importance of the Arg metabolism in the complex pathogenesis of atherosclerosis.
A comprehensive study by Ryoo et al 107 identified endothelial ARG as a novel target for atherosclerosis. Both pharmacological inhibition with BEC (S-[2-boronoethyl]-Lcysteine) and genetic depletion of ARG2 prevented cholesterol-mediated vascular dysfunction. Intriguingly, long-term treatment with the ARG inhibitor BEC reduced plaque burden, indicating a promising approach for clinical translation. However, other studies proposed anti-inflammatory effects of ARG1 by reducing inflammatory cytokine secretion and promoting VSMC proliferation, rather suggesting a beneficial role of ARG1 in atherosclerosis. 108, 109 Considering that ARG1 is predominantly expressed in anti-inflammatory M2 macrophages ( Figure 2B ), a recent study specifically interrogated the contribution of hematopoietic ARG1 on atherosclerosis susceptibility. Despite decreased leukocytosis and increased foam cell formation, no effects on plaque burden could be demonstrated, indicating a cell-specific role of ARG-modulation. 110 Although the definitive role of ARG in atherosclerosis remains elusive, future studies using isoformspecific modulators and cell-specific models might unravel specifically targetable therapies for atherosclerosis.
Pharmacological Intervention
As outlined above, the therapeutic concept of Arg supplementation failed to improve cardiovascular outcome. One novel pharmacological approach represents the inhibition of ARG. In a recent clinical trial, Nor-NOHA (N ω -hydroxy-nor-L-arginine), an unspecific ARG inhibitor, markedly improved endothelial function indicating that increased ARG activity contributes to the development of endothelial dysfunction (http://www.clinicaltrials.gov. Unique identifier: NCT02009527). 111 However, pharmacological inhibitors of both ARG and NOS still lack specificity, which challenges the development of targeted therapies because nonspecific activities are likely to be expected. Interestingly, all therapeutic approaches tested in CVD only target the endothelial component of Arg metabolism, whereas its immune regulatory functions remain elusive.
Homoarginine
Clinical and Epidemiological Evidence
During the past decade, low hArg has been established as a novel biomarker for CVD that has also been independently associated with cardiovascular and all-cause mortality. 26, 112 This link has been extended towards cerebrovascular disease demonstrating that low hArg predicts fatal strokes 113 as well as short and long-term outcome after acute ischemic stroke. 30 In the general population, high hArg was associated with lower risk for cardiovascular events and mortality; likewise, an inverse association between hArg and subclinical vascular disease was observed. 114 To substantiate whether low hArg is causally linked to impaired cardiovascular outcome, a Mendelian randomization analysis using the hArg-associated AGAT variants was performed. However, no evidence for a causal link between hArg and cardiometabolic outcomes was reported. 115 In conclusion, observational studies clearly suggest a harmful effect of low hArg in CVD; however, causality between hArg and cardiovascular outcome, and specifically the association with atherosclerosis, still remains elusive and warrants further clinical and experimental investigation.
Experimental Evidence
Experimental evidence emphasizes a direct causal relationship between hArg and cardiovascular outcome when considering ischemic stroke size was larger in hArg-deficient AGAT mice, which was rescued by hArg supplementation. 30 Recently, these observations have been extended to the heart showing that hArg-deficient AGAT mice were characterized by a pronounced hemodynamic phenotype consisting of low heart rate, impaired contractility, and impaired relaxationall of which were rescued by hArg supplementation. 116 Importantly, supplementation in normal wild-type mice does not affect resting blood pressure, but it does preserve cardiac function in postischemic heart failure. 117 In summary, this data suggests that hArg levels directly influence cardiovascular and cerebrovascular outcome, although the underlying mechanism is still lacking. Ischemic stroke and post-MI (myocardial infarction) heart failure share atherosclerosis as underlying pathology; however, experimental evidence on hArg in atherosclerosis remains vague to date. Whereas one study showed that hArg accelerates osteogenic/chondrogenic transformation of VSMCs and vascular calcification, 118 another study reported that hArg reduces neointimal formation in balloon-injured rat carotids. 119 However, neither study was performed under atherosclerotic conditions. Notably, recent data from our group show a beneficial effect of dietary hArg supplementation in apoE-deficient mice, as reflected by a decrease in lesion size. Mechanistic experiments further suggest that hArg modulates T-cell activity (Atzler et al, unpublished data, 2018) , supporting the hypothesis that metabolic changes in immune cells contribute to the pathogenesis of atherosclerosis.
Pharmacological Intervention
Current research implies 2 different approaches of hArg intervention: AGAT-dependent hArg modulation and dietary hArg supplementation. To date, only the latter has entered the next phase of clinical translation. A recent first-in-man study demonstrated that oral hArg administration once daily significantly increased plasma levels and, importantly, was safe and well tolerated (http://www.clinicaltrials.gov. Unique identifier: NCT02675660). 39 Based on this, a randomized control trial has currently started to study the applicability of oral hArg administration in patients with acute ischemic stroke and low hArg serum concentration (http://www.clinicaltrials.gov. Unique identifier: NCT03692234). In synopsis, hArg supplementation is a promising approach for clinical translation; however, the underlying mechanisms still need to be validated to warrant better identification of patient subgroups benefiting from hArg therapy.
Tryptophan
Clinical and Epidemiological Evidence
In a variety of infectious, autoimmune, and malignant diseases, as well as mood disorders, clinical research has identified low levels of Trp. 120 However, more recent data emphasize a predictive role of IDO-mediated Trp metabolites in CVD, which interestingly goes hand in hand with emerging evidence for the inflammatory hypothesis of atherosclerosis. As a surrogate for IDO activity, the plasma kynurenine to Trp ratio (kynurenine:Trp) was found to be increased in patients with CVD 121 and correlates with established CVD risk factors and markers of subclinical atherosclerosis. 122 In patients with stable angina pectoris, kynurenine:Trp predicted the incidence of cardiovascular events, such as MI and mortality, independently of established cardiovascular risk markers. 123, 124 Likewise, MI patients with low Trp and high kynurenic acid were at a higher risk for death or recurrent MI. In contrast to previous findings, neither kynurenine nor kynurenine:Trp levels were associated with clinical outcomes in this cohort. 125 In patients with chronic kidney disease, 3-hydroxy-kynurenine was associated with the prevalence of CVD, whereas the further downstream metabolites 3-HAA and quinolinic acid showed independent associations with inflammation and subclinical atherosclerosis, namely intima-media thickness, respectively. 126, 127 Future in-depth studies appear warranted to validate the potential of Trp metabolites for implementation as clinical biomarkers in CVD.
Experimental Evidence
We have highlighted the importance of Trp and its IDO-dependent metabolism on immune cells, as well as the effects of modulating this pathway. However, experimental evidence in atheroinflammation remains controversial. Recently, 2 independent studies unraveled contradictory findings on the role of Ido1-deficiency in atherosclerosis. First, Metghalchi et al 125 provided unsuspected evidence that Ido1-deficiency reduces the development of atherosclerosis in LDL receptor (LDLr)-deficient mice on high-fat diet. Mechanistically, they proposed IDO1-mediated suppression of the atheroprotective cytokine IL-10, which was further supported by an increase in IL-10 in macrophages lacking IDO1. In parallel, Cole et al 128 demonstrated an atheroprotective role for IDO1 in apoE-deficient mice. Here, Ido1-deficiency resulted in increased lesion size after 15 and 20 weeks of normal chow diet along with a decrease in IL-10 production, suggesting that IDO1 locally activates myeloid cells followed by a systemic increase in IL-10 production. Notably, using a different Ido-deficient mouse model, Van de Velde et al 129 provided evidence against the proposed negative effects of IDO1 on IL-10 production in myeloid cells. Furthermore, administration of the Trp metabolite 3-HAA reduced lesion size in LDLr −/− mice by regulating both lipid metabolism and vascular inflammation. 130 In line, Cole et al 128 further showed that administration of the orally active synthetic 3-HAA analog 3,4-DAA (N-(3,4-dimethoxycinnamoyl)-anthranilic acid; Tranilast) reduced the release of proinflammatory cytokines and prevented atherosclerotic plaque development. 128 Taken together, experimental evidence strengthened the idea that IDO-mediated Trp metabolism crucially contributes to the pathogenesis of atherosclerosis. Further research on immune cell-specific pathway-manipulation along with a precise assignment of the immunomodulatory properties of the 2 IDO isoforms and subsequent Trp metabolites may shed light on promising new therapeutic targets.
Pharmacological Intervention
Until now, little is known about the therapeutic potential of Trp-modulation in CVD. One approach, which is currently under clinical investigation, is the administration of the synthetic Trp metabolite 3,4-DAA (Tranilast). In line with the experimental data above, treatment with Tranilast modulated proinflammatory cytokines and reduced lesion size in a human ex vivo atheroma model. 128 In a large randomized control trial on patients with percutaneous coronary intervention, Tranilast failed its primary goal, the reduction of restenosis. Interestingly though, treatment with Tranilast reduced the incidence of MI, which may indicate that Tranilast may exert anti-inflammatory effects instead of modulating VSMC proliferation. 131 This anti-inflammatory concept is currently tested in several randomized control trials with patients with other chronic inflammatory diseases, like rheumatoid arthritis, mucinoses, or gout. However, no randomized control trial has been conducted to date to elaborate the benefit of Tranilast in patients with atherosclerosis.
Altogether, experimental and clinical data clearly establish a role for the metabolism of arginine, homoarginine, and tryptophan in inflammation and CVD. It is important to note, however, that supplementation of these AAs, or their metabolites, alone has not been shown to reverse the course of atherosclerosis. As we previously discussed, current therapies, including statins and PCSK9 inhibitors, are recommended because of their lipid-lowering properties, but ultimately they still leave a large residual CVD risk in the general population. 8, 10 Antiinflammatory approaches, such as AA supplementation or targeted metabolism modulation, may help decrease this risk in the future. Combination therapy, including lipid-lowering drugs together with anti-inflammatory drugs, could be the first step towards personalized medicine in the field of CVD.
Conclusions
In this review, we have summarized the current knowledge surrounding the role of the AAs Arg, hArg, and Trp and their metabolism in the context of atheroinflammation.
Decades of cardiovascular research have established the inflammatory hypothesis of atherosclerosis, which recently culminated in the success of the pivotal CANTOS trial. These intriguing findings have opened ample options for novel anti-inflammatory therapies targeting specific aspects of the immune system. It has been described that cyclic effects between ECs, innate, and adaptive immune cells occur during Arg and hArg, as well as Trp metabolism. The local inflammatory environment in combination with AA bioavailability directs a complex set of interactions between innate and adaptive immune cells, which affects polarization and proliferation of both cell types. Although we have described what is currently known about the biological function of those AAs, the underlying mechanisms in the pathogenesis of atherosclerosis remain to be clarified. Nevertheless, first approaches in targeting AA metabolism, including Arg, hArg, and Trp, as well as their downstream metabolites, suggest promising strategies for clinical interventions for patients with CVD.
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